Inactive Instrument

Jounce Therapeutics, Inc.

Equities

JNCE

US4811161011

Biotechnology & Medical Research

Jounce Therapeutics : to Present at Upcoming Investor Conferences in January

January 11, 2021 at 09:30 am EST

CAMBRIDGE - Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will present at two upcoming investor conferences.

H.C. Wainwright BioConnect 2021 Conference: A webcast presentation will be available on demand during the conference, starting Monday, January 11, 2021 at 6:00 a.m. ET.

39th Annual J.P. Morgan Healthcare Conference: A live webcast will take place on Thursday, January 14, 2021 at 8:20 a.m. ET.

A webcast of each presentation will be available by visiting 'Events and Presentations' in the Investors and Media section of Jounce's website at www.jouncetx.com. The webcasts will be archived for 30 days following the presentations.

About Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce's lead macrophage program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce's internal PD-1 inhibitor, or pembrolizumab has begun screening patients with advanced solid tumors. Jounce's most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce's broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc.

Contact:

Malin Deon

Tel: +1-857-259-3843

Email: mdeon@jouncetx.com

Latest news about Jounce Therapeutics, Inc.

Graphite Bio, Inc. Announces Executive Changes	23-08-23	CI
Jounce Therapeutics, Inc. Announces Board Changes	23-05-04	CI
Jounce Therapeutics, Inc.(NasdaqGS:JNCE) dropped from NASDAQ Composite Index	23-05-04	CI
Jounce Therapeutics, Inc.(NasdaqGS:JNCE) dropped from S&P Global BMI Index	23-05-04	CI
Jounce Therapeutics, Inc.(NasdaqGS:JNCE) dropped from S&P TMI Index	23-05-04	CI
Concentra Biosciences, LLC completed the acquisition of Jounce Therapeutics, Inc. from Tang Capital Management, LLC and others.	23-05-02	CI
Redx confirms Jounce deal lapses, Tirupati seals deal	23-04-03	AN
Redx Pharma Shares Fall 5% as Merger With Jounce Therapeutics Fails	23-04-03	MT
Jounce Therapeutics, Inc. Expects Resignation of Elizabeth Trehu as Chief Medical Officer	23-03-30	CI
Sector Update: Health Care Stocks Rise in Late Trading	23-03-27	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	23-03-27	MT
European Stock Markets Close Higher Monday as First Citizens BancShares' Planned Acquisition of Silicon Valley Bank Assets, Deposits Eases Banking Crisis Fears	23-03-27	MT
Piper Sandler Downgrades Jounce Therapeutics to Neutral From Overweight, Adjusts Price Target to $1.85 From $5	23-03-27	MT
Jounce dumps Redx Pharma for acquisition by Concentra; to cut 84% of jobs	23-03-27	RE
Redx Pharma Says Jounce Therapeutics Terminated Merger Deal; Shares Plunge 19%	23-03-27	MT
Jounce Therapeutics Agrees to be Acquired by Concentra Biosciences	23-03-27	MT
Redx Pharma's bid to buy Jounce snubbed by Concentra's higher offer	23-03-27	AN
Jounce Therapeutics, Inc. completed the acquisition of Redx Pharma Plc from a group of sellers and other shareholders.	23-03-26	CI
Jounce Therapeutics, Inc. Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer	23-03-16	CI
Sector Update: Health Care Stocks' Late Recovery Stalls	23-03-15	MT
Sector Update: Health Care Stocks Moderately Lower	23-03-15	MT
Top Midday Gainers	23-03-15	MT
Sector Update: Health Care Stocks Retreat Pre-Bell Wednesday	23-03-15	MT
Redx Pharma Says Merger Target Jounce Therapeutics Received New Takeover Proposal; Stock Surges 34%	23-03-15	MT
Sector Update: Health Care	23-03-15	MT

Chart Jounce Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It is engaged in the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Its pipeline is focused on product candidates to address PD-(L)1-inhibitor resistant and PD-(L)1 inhibitor sensitive tumors. Its program, JTX-8064, is a tumor-associated macrophage candidate from its Translational Science platform. JTX-8064 is a monoclonal antibody that binds to Leukocyte Immunoglobulin Like Receptor B2, (LILRB2), which is a cell surface receptor expressed on macrophages and other myeloid cells. JTX-1484 is a monoclonal antibody designed to block human Leukocyte Immunoglobulin Like Receptor B4, (LILRB4) on various myeloid cells. Its product candidate, vopratelimab, is a monoclonal antibody that binds to and activates T cell CO-Stimulator (ICOS). It also develops JTX-1484 and JTX-2134 product candidates.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-1.08%	105B
REGENERON PHARMACEUTICALS, INC.	+4.13%	97.5B
ARGENX SE	+1.80%	22.19B
BIONTECH SE	-15.43%	21.33B
GENMAB A/S	-8.24%	18.68B
WUXI APPTEC CO., LTD.	-41.41%	16.6B
BEIGENE, LTD.	-20.24%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+6.96%	14.09B
SAREPTA THERAPEUTICS, INC.	+22.43%	10.99B

Bio Therapeutic Drugs